RemoteA Oy will receive a 1,2 € million grant for the implementation of Horizon 2020 SME Instrument phase 2 project
Cardiovascular diseases (CVD) treatment is the most critical and expensive healthcare problem in EU. Still the wider uptake of more advanced patient analysis tools (e.g. home-monitoring devices) or new treatment practices (e.g. 72-hour or even 7-day ECG analysis) are held back by clinics and medical professionals because the increasing data volumes cannot be analysed with current resources. RemoteA has developed a smart algorithm for automatic interpretation of ECG analysis tool providing a simple and secure telemedicine service platform for fast specialist consultations for cardiovascular diseases diagnostics and treatment.
SME Instrument is a dedicated funding instrument under the Horizon 2020 Research and Innovation programme that supports innovative SMEs in Europe. The instrument aims to fill the gaps in funding for research and innovation at early stages and thereby accelerate the exploitation of novel solutions to address key societal challenges. Applications are expected in various topics and companies can apply for funding as single applicants or with partners. Subcontracting is allowed both in phase 1 and phase 2 projects.
Original article published here.